Ignace Vergote

33PUBLICATIONS
333CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Oct 30, 2025
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.

Kristoffer Staal Rohrberg, Juanita S Lopez, Mohammed M Milhem

|May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium.

Nicole Concin, Ioana Braicu, Pierre Combe

|Dec 14, 2024
Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25.

Coline Montégut, Claire Falandry, Saverio Cinieri

|Dec 05, 2024
Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.

Hailei Zhang, Anna Rutkowska, Antonio González-Martín

|Apr 16, 2024
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.

Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega

|Mar 28, 2024
TIM3 Checkpoint Inhibition Fails to Prolong Survival in Ovarian Cancer-Bearing Mice.

Yani Berckmans, Ann Vankerckhoven, Aarushi Audhut Caro

Pageof 6

Frequent Collaborators

6 joint publications

Bradley J Monk

5 joint publications

Jalid Sehouli

5 joint publications

David Cibula

5 joint publications

Isabelle Ray-Coquard